Diagnosis & Screening Trials
Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.
STUDY22026
Health Education Approach to Lung Screening (HEALS) - Lung Cancer Screening and Biospecimen Collection Through a Patient Navigation Approach
Evaluate the impact of the patient navigation program on the proportion of patients who complete LCS, defined as undergoing an LDCT. Assess the feasibility and acceptability of the patient navigation program. Assess the impact of the patient navigation program on patient health related quality of life. Assess the impact of the patient navigation program on patient financial distress.
Study InformationSTUDY26651
MYELOMATCH, Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MyeloMATCH Clinical Trials
To evaluate the feasibility of MATCHBox organizing all specimen testing results needed for assignment to a myeloMATCH clinical trial or Tier Advancement Pathway (TAP) within one hor prior to the first Treatment Verfication Cell had 4 days after MDNet receipt of all required specimens for initial therapy and within 11 days for subsequent therapies.
Study InformationSTUDY26655
A Multi-Center Screening Study to Characterize the Prevalence of the KIT D816V Mutation in Patients with Suspected Clonal Mast Cell Disease
Characterize the prevalence of the KIT D816V mutation in PB samples from participants with SMAC.
Study InformationSTUDY27325
Surgical drain fluid for detection of molecular residual disease (MRD) in patients with bladder, renal, and urothelial cancers
To investigate if DNA cancer-associated-variants (CAV) in post-operative blood, tumor tissue, and surgical drain fluid can correlate molecular residual disease (MRD) with clinical, radiographic, or pathologic progression at 12- and 24- months post-surgery in patients with bladder, renal, and upper tract urothelial cancer.
Study InformationSTUDY27490
B-Brilliant
To compare the conspicuity and visibility of calcifications and other lesion types between narrow-angle breast tomosynthesis (NBT) and wide-angle breast tomosynthesis (WBT) systems. Our specific aim will be achieved through two enrollment arms.
Study InformationSTUDY28561
Blue Light Cystoscopy with Cysview Registry
The purpose of the registry is to study the use of BLC with Cysview® in clinical practice in the United States. Data will be captured on specific patient types undergoing BLC with Cysview® for suspected or known lesion(s) on the basis of a prior cystoscopy, or in patients undergoing surveillance cystoscopy for carcinoma of the bladder. Specific clinical questions will be asked.
Study InformationSTUDY29056
Case-Control Study of a Novel Test for the Early Detection of Hepatocellular Carcinoma in at-risk Patients with Cirrhosis
To determine the diagnostic accuracy of the novel Hepatocellular Carcinoma (HCC) Test developed by Curve Biosciences in terms of area under the receiver operating characteristic curve (AUROC), sensitivity, and specificity for the differentiation of patients with HCC from those without HCC in the at-risk population.
Study InformationSTUDY29293
Racial Differences in Patient-Reported Quality of Life Among Prostate Cancer Patients Across Treatment Modalities
To evaluate racial differences in patient-reported quality-of-life outcomes among patients treated for prostate cancer at MUSC using EPIC-50 domain scores.
Study Information